Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1998 Apr 15;26(8):2016–2023. doi: 10.1093/nar/26.8.2016

Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.

E G Marcusson 1, B Bhat 1, M Manoharan 1, C F Bennett 1, N M Dean 1
PMCID: PMC147486  PMID: 9518498

Abstract

Antisense oligonucleotides complementary to specific mRNA sequences are widely used inhibitors of gene expression in vitro and in vivo . In vitro cationic lipids have been demonstrated to increase the pharmacological activity of antisense oligonucleotides by increasing cellular uptake and facilitating nuclear accumulation. We have investigated the intracellular fate of oligonucleotide/cationic lipid complexes using fluorescently labeled lipids and oligonucleotides targeted to protein kinase C-alpha. After addition to cells the lipids initially co-localized with the oligonucleotide on the cell surface and in fine punctate structures within the cytoplasm. At later times the oligonucleotide began to accumulate in the nucleus as well as the cytoplasm. In contrast, the cationic lipid remained localized to the cell surface and the cytoplasm and was never found in the nucleus. Expression of protein kinase C-alpha mRNA did not begin to decline until after oligonucleotide was seen in the nucleus. This was also coincident with the transient appearance of a smaller mRNA transcript believed to result from RNase H cleavage of protein kinase C-alpha mRNA. These data suggest that although cationic lipids facilitate uptake of oligonucleotides, the complex must disassociate before the oligonucleotide can gain access to the nucleus and induce degradation of targeted mRNA.

Full Text

The Full Text of this article is available as a PDF (2.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595–7599. doi: 10.1073/pnas.88.17.7595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alahari S. K., Dean N. M., Fisher M. H., Delong R., Manoharan M., Tivel K. L., Juliano R. L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1996 Oct;50(4):808–819. [PubMed] [Google Scholar]
  3. Beltinger C., Saragovi H. U., Smith R. M., LeSauteur L., Shah N., DeDionisio L., Christensen L., Raible A., Jarett L., Gewirtz A. M. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest. 1995 Apr;95(4):1814–1823. doi: 10.1172/JCI117860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennett C. F., Chiang M. Y., Chan H., Shoemaker J. E., Mirabelli C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1992 Jun;41(6):1023–1033. [PubMed] [Google Scholar]
  5. Bergan R., Connell Y., Fahmy B., Neckers L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 1993 Jul 25;21(15):3567–3573. doi: 10.1093/nar/21.15.3567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bielinska A., Kukowska-Latallo J. F., Johnson J., Tomalia D. A., Baker J. R., Jr Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 1996 Jun 1;24(11):2176–2182. doi: 10.1093/nar/24.11.2176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bijsterbosch M. K., Manoharan M., Rump E. T., De Vrueh R. L., van Veghel R., Tivel K. L., Biessen E. A., Bennett C. F., Cook P. D., van Berkel T. J. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. 1997 Aug 15;25(16):3290–3296. doi: 10.1093/nar/25.16.3290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bongartz J. P., Aubertin A. M., Milhaud P. G., Lebleu B. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 1994 Nov 11;22(22):4681–4688. doi: 10.1093/nar/22.22.4681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Boussif O., Lezoualc'h F., Zanta M. A., Mergny M. D., Scherman D., Demeneix B., Behr J. P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297–7301. doi: 10.1073/pnas.92.16.7297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Butler M., Stecker K., Bennett C. F. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest. 1997 Oct;77(4):379–388. [PubMed] [Google Scholar]
  11. Chiang M. Y., Chan H., Zounes M. A., Freier S. M., Lima W. F., Bennett C. F. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162–18171. [PubMed] [Google Scholar]
  12. Chin D. J., Green G. A., Zon G., Szoka F. C., Jr, Straubinger R. M. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol. 1990 Dec;2(12):1091–1100. [PubMed] [Google Scholar]
  13. Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7031–7035. doi: 10.1073/pnas.89.15.7031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cossum P. A., Sasmor H., Dellinger D., Truong L., Cummins L., Owens S. R., Markham P. M., Shea J. P., Crooke S. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181–1190. [PubMed] [Google Scholar]
  15. Crooke S. T., Bennett C. F. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:107–129. doi: 10.1146/annurev.pa.36.040196.000543. [DOI] [PubMed] [Google Scholar]
  16. Dean N. M., McKay R., Condon T. P., Bennett C. F. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem. 1994 Jun 10;269(23):16416–16424. [PubMed] [Google Scholar]
  17. Dean N. M., McKay R. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11762–11766. doi: 10.1073/pnas.91.24.11762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dean N., McKay R., Miraglia L., Howard R., Cooper S., Giddings J., Nicklin P., Meister L., Ziel R., Geiger T. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. 1996 Aug 1;56(15):3499–3507. [PubMed] [Google Scholar]
  19. Delong R., Stephenson K., Loftus T., Fisher M., Alahari S., Nolting A., Juliano R. L. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci. 1997 Jun;86(6):762–764. doi: 10.1021/js960409f. [DOI] [PubMed] [Google Scholar]
  20. Geselowitz D. A., Neckers L. M. Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev. 1992 Spring;2(1):17–25. doi: 10.1089/ard.1992.2.17. [DOI] [PubMed] [Google Scholar]
  21. Gewirtz A. M. Developing oligonucleotide therapeutics for human leukemia. Anticancer Drug Des. 1997 Jul;12(5):341–358. [PubMed] [Google Scholar]
  22. Goodarzi G., Watabe M., Watabe K. Binding of oligonucleotides to cell membranes at acidic pH. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1343–1351. doi: 10.1016/0006-291x(91)92086-y. [DOI] [PubMed] [Google Scholar]
  23. Guy-Caffey J. K., Bodepudi V., Bishop J. S., Jayaraman K., Chaudhary N. Novel polyaminolipids enhance the cellular uptake of oligonucleotides. J Biol Chem. 1995 Dec 29;270(52):31391–31396. doi: 10.1074/jbc.270.52.31391. [DOI] [PubMed] [Google Scholar]
  24. Hartmann G., Krug A., Eigler A., Moeller J., Murphy J., Albrecht R., Endres S. Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):291–299. doi: 10.1089/oli.1.1996.6.291. [DOI] [PubMed] [Google Scholar]
  25. Hughes J. A., Aronsohn A. I., Avrutskaya A. V., Juliano R. L. Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Pharm Res. 1996 Mar;13(3):404–410. doi: 10.1023/a:1016044609972. [DOI] [PubMed] [Google Scholar]
  26. Illinger D., Kuhry J. G. The kinetic aspects of intracellular fluorescence labeling with TMA-DPH support the maturation model for endocytosis in L929 cells. J Cell Biol. 1994 May;125(4):783–794. doi: 10.1083/jcb.125.4.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kanaya S., Ikehara M. Functions and structures of ribonuclease H enzymes. Subcell Biochem. 1995;24:377–422. doi: 10.1007/978-1-4899-1727-0_12. [DOI] [PubMed] [Google Scholar]
  28. Krieg A. M., Tonkinson J., Matson S., Zhao Q., Saxon M., Zhang L. M., Bhanja U., Yakubov L., Stein C. A. Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1048–1052. doi: 10.1073/pnas.90.3.1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Legendre J. Y., Szoka F. C., Jr Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm Res. 1992 Oct;9(10):1235–1242. doi: 10.1023/a:1015836829670. [DOI] [PubMed] [Google Scholar]
  30. Leonetti J. P., Degols G., Lebleu B. Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconjug Chem. 1990 Mar-Apr;1(2):149–153. doi: 10.1021/bc00002a010. [DOI] [PubMed] [Google Scholar]
  31. Leonetti J. P., Mechti N., Degols G., Gagnor C., Lebleu B. Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2702–2706. doi: 10.1073/pnas.88.7.2702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lewis J. G., Lin K. Y., Kothavale A., Flanagan W. M., Matteucci M. D., DePrince R. B., Mook R. A., Jr, Hendren R. W., Wagner R. W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3176–3181. doi: 10.1073/pnas.93.8.3176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Loke S. L., Stein C. A., Zhang X. H., Mori K., Nakanishi M., Subasinghe C., Cohen J. S., Neckers L. M. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989 May;86(10):3474–3478. doi: 10.1073/pnas.86.10.3474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ma D. D., Wei A. Q. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk Res. 1996 Nov-Dec;20(11-12):925–930. doi: 10.1016/s0145-2126(96)00062-8. [DOI] [PubMed] [Google Scholar]
  35. Monia B. P., Johnston J. F., Ecker D. J., Zounes M. A., Lima W. F., Freier S. M. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem. 1992 Oct 5;267(28):19954–19962. [PubMed] [Google Scholar]
  36. Nakai D., Seita T., Terasaki T., Iwasa S., Shoji Y., Mizushima Y., Sugiyama Y. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J Pharmacol Exp Ther. 1996 Sep;278(3):1362–1372. [PubMed] [Google Scholar]
  37. Presper K. A., Basu M., Basu S. Biosynthesis in vitro of fucose-containing glycosphingolipids in human neuroblastoma IMR-32 cells. Proc Natl Acad Sci U S A. 1978 Jan;75(1):289–293. doi: 10.1073/pnas.75.1.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sharma H. W., Narayanan R. The therapeutic potential of antisense oligonucleotides. Bioessays. 1995 Dec;17(12):1055–1063. doi: 10.1002/bies.950171210. [DOI] [PubMed] [Google Scholar]
  39. Simons M., Edelman E. R., DeKeyser J. L., Langer R., Rosenberg R. D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992 Sep 3;359(6390):67–70. doi: 10.1038/359067a0. [DOI] [PubMed] [Google Scholar]
  40. Spiller D. G., Tidd D. M. The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. Anticancer Drug Des. 1992 Apr;7(2):115–129. [PubMed] [Google Scholar]
  41. Stewart A. J., Pichon C., Meunier L., Midoux P., Monsigny M., Roche A. C. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine. Mol Pharmacol. 1996 Dec;50(6):1487–1494. [PubMed] [Google Scholar]
  42. Takle G. B., Thierry A. R., Flynn S. M., Peng B., White L., Devonish W., Galbraith R. A., Goldberg A. R., George S. T. Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):177–185. doi: 10.1089/oli.1.1997.7.177. [DOI] [PubMed] [Google Scholar]
  43. Thierry A. R., Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 1992 Nov 11;20(21):5691–5698. doi: 10.1093/nar/20.21.5691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Thierry A. R., Rahman A., Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun. 1993 Feb 15;190(3):952–960. doi: 10.1006/bbrc.1993.1142. [DOI] [PubMed] [Google Scholar]
  45. Wagner R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994 Nov 24;372(6504):333–335. doi: 10.1038/372333a0. [DOI] [PubMed] [Google Scholar]
  46. Walker I., Irwin W. J., Akhtar S. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res. 1995 Oct;12(10):1548–1553. doi: 10.1023/a:1016260110049. [DOI] [PubMed] [Google Scholar]
  47. Wang S., Lee R. J., Cauchon G., Gorenstein D. G., Low P. S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3318–3322. doi: 10.1073/pnas.92.8.3318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Watson P. H., Pon R. T., Shiu R. P. Inhibition of cell adhesion to plastic substratum by phosphorothioate oligonucleotide. Exp Cell Res. 1992 Oct;202(2):391–397. doi: 10.1016/0014-4827(92)90091-l. [DOI] [PubMed] [Google Scholar]
  49. Wu G. Y., Wu C. H. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem. 1992 Jun 25;267(18):12436–12439. [PubMed] [Google Scholar]
  50. Wyman T. B., Nicol F., Zelphati O., Scaria P. V., Plank C., Szoka F. C., Jr Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry. 1997 Mar 11;36(10):3008–3017. doi: 10.1021/bi9618474. [DOI] [PubMed] [Google Scholar]
  51. Yakubov L. A., Deeva E. A., Zarytova V. F., Ivanova E. M., Ryte A. S., Yurchenko L. V., Vlassov V. V. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci U S A. 1989 Sep;86(17):6454–6458. doi: 10.1073/pnas.86.17.6454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Yazaki T., Ahmad S., Chahlavi A., Zylber-Katz E., Dean N. M., Rabkin S. D., Martuza R. L., Glazer R. I. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol. 1996 Aug;50(2):236–242. [PubMed] [Google Scholar]
  53. Zabner J., Fasbender A. J., Moninger T., Poellinger K. A., Welsh M. J. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 1995 Aug 11;270(32):18997–19007. doi: 10.1074/jbc.270.32.18997. [DOI] [PubMed] [Google Scholar]
  54. Zelphati O., Szoka F. C., Jr Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res. 1996 Sep;13(9):1367–1372. doi: 10.1023/a:1016026101195. [DOI] [PubMed] [Google Scholar]
  55. Zelphati O., Szoka F. C., Jr Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11493–11498. doi: 10.1073/pnas.93.21.11493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Zhao Q., Matson S., Herrera C. J., Fisher E., Yu H., Krieg A. M. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev. 1993 Spring;3(1):53–66. doi: 10.1089/ard.1993.3.53. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES